Answers are grounded in this paper and cite their sources.
Faricimab is estimated to be a cost-effective treatment option compared with aflibercept for nAMD from a US payer perspective. This finding may support its inclusion in treatment guidelines and formulary decisions, pending confirmation in real-world practice.
No takes yet. Share an insight, caveat, or question.
Baljoon et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: